All posts by admin

11Feb/14

FDA Investigating Heart Failure Risk Linked To Onglyza – Forbes


Drug Discovery & Development

FDA Investigating Heart Failure Risk Linked To Onglyza
Forbes
ureThe FDA said today that it was conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin is marketed by AstraZeneca AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca 
FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure RiskU.S. News & World Report
FDA to probe saxagliptin’s heart failure riskFamily Practice News Digital Network
FDA Investigating Heart Failure Risks with SaxagliptinDrug Discovery & Development
Healio
all 27 news articles »
11Feb/14

Study: Resilience in parents of children undergoing stem cell transplant – Science Codex

Study: Resilience in parents of children undergoing stem cell transplant
Science Codex
A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress at the time
Children’s Medical Center to Host 23rd Annual ‘Be The Match’ Donor Registry The Herald | HeraldOnline.com (press release)

all 5 news articles »

11Feb/14

Study: Resilience in Parents of Children Undergoing Stem Cell Transplant – Newswise (press release)

Study: Resilience in Parents of Children Undergoing Stem Cell Transplant
Newswise (press release)
Newswise — A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress

11Feb/14

Gilead seeks approval for Hepatitis C drug that's innovative — and expensive – San Francisco Chronicle (blog)

Gilead seeks approval for Hepatitis C drug that’s innovative — and expensive
San Francisco Chronicle (blog)
Gilead is also taking heat internationally for its plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $2,500 for six months of treatment, according to an interview with an Indian pharmaceutical